Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Momelotinib for VEXAS syndrome
jRCT2021260044Phase 3Not yet recruiting
- Sponsor
- GSK
- Start
- Sep 2026
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of mivavotinib in VEXAS syndrome (VEXAS) (3 arms), sponsored by GSK. Primary endpoint: Objective response rate at Week 26. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
mivavotinib
03
Conditions
VEXAS syndrome (VEXAS)
Beyond the preview
Go deeper on jRCT2021260044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021260044.